reports
EQS-News: Volta Medical wurde in die neueste Richtlinie der führenden ...
EQS-News: Volta Medical SAS / Schlagwort(e): Sonstiges Volta Medical wurde in die neueste Richtlinie der führenden internationalen Gesellschaften für kardiale Elektrophysiologie zur Ablation von Vorhofflimmern aufgenommen 09.05.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Volta Medical wurde in die neueste Richtlinie der führenden internationalen Gesellschaften für kardiale Elektrophysiologie zur Ablation von Vorhofflimmern aufgenommen Die im EP Europace Journal veröffentlichte Richtlinie würdigt die KI-basierte Begle...
Genel Energy PLC: Results of AGM
Genel Energy PLC (GENL) Genel Energy PLC: Results of AGM 09-May-2024 / 13:00 GMT/BST 9 May 2024 Genel Energy plc Results of Annual General Meeting 9 May 2024 The Annual General Meeting of Genel Energy plc was held today, Thursday, 9 May 2024 and the results of the votes by shareholders are set out below. The number of ordinary shares of £0.10p each in the Company in issue at the date of the meeting was 279,402,863 and each share attracted one vote. The results were as follows: Resolutions For % Against % ...
Holding(s) in Company
easyJet plc (EZJ) Holding(s) in Company 09-May-2024 / 13:00 GMT/BST TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B7KR2P84 Issuer Name EASYJET PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Bank of America Corporation City of registered office (if applicable) Country of registered office (if applicable) US 4. Details of the shareholder Full name of shareholder(...
EQS-News: Volta Medical Featured in Latest Consensus Statement from Le...
EQS-News: Volta Medical SAS / Key word(s): Miscellaneous Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation 09.05.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation Published in the EP Europace Journal, the consensus statement highlights Volta’s AI Companion and the TAILORED-AF clinical tr...
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Mi...
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively Reported positive proof-of-concept for lonigutamab in thyroid eye disease patients and positive top-line Phase 2b/3 data for izokibep in psoriatic arthritis Cash, cash equivalents, and short-term marketable securities at March 31, 2024 of $678.5 million Company...
Sportradar to Participate in the J.P. Morgan Global Technology, Media ...
Sportradar to Participate in the J.P. Morgan Global Technology, Media and Communications Conference on May 21 ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten Koerl, Chief Executive Officer, will participate in the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel on Tuesday, May 21, 2024. Mr. Koerl will participate in a fireside chat at 8:10 a.m. EST that morning and that will be webcast...
Bonjour Holdings: 1 director
A director at Bonjour Holdings sold 50,000,000 shares at 0.060HKD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
VYNE Reports First Quarter 2024 Financial Results and Provides Busines...
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarterPhase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo and will evaluate VYN201 gel in 1%, 2% and 3% concentrations compared to vehicle for 24 weeks, followed by a 28-week active treatment extensionIND clearance received for oral BD2-selective BET inhibitor, VYN202; anticipate first healthy volunteers to be dosed in Phase 1a SAD/MAD trial this quarter B...
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarte...
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first patients in TANDEM, pivotal Phase 3 trial evaluating fixed-dose combination of obicetrapib and ezetimibe; topline data expected in 1Q 2025 -- -- Company to host R&D event on May 16, 2024, beginning at 9:00 a.m. ET in New York City – -- Strong financial position; ending the quarter with $481...
RAPT Therapeutics Reports First Quarter 2024 Financial Results
RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141.6 million SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024. The Company also announced today that it has decided to close and unbl...
Abcourt confirme une deuxième zone minéralisée en or à l'est du gîte F...
Abcourt confirme une deuxième zone minéralisée en or à l'est du gîte Flordin vers le secteur Cartwright dans la région de Lebel-sur-Quévillon ROUYN-NORANDA, Québec, 09 mai 2024 (GLOBE NEWSWIRE) -- Mines Abcourt Inc. (« Abcourt » ou la « Société ») (Bourse de croissance TSX : ABI) est heureux de confirmer une deuxième zone minéralisée en or à l'est du gîte Flordin vers le gîte Cartwright détenu à 100% par Abcourt. Faits saillants •Une étude pétrographique confirme la présence de grains d’or dans la pyrite. Ces grains d’or seraient associés à la seconde phase de cristallisation de la py...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results a...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full quarter of launch Cigna Healthcare recently added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of all U.S. commercial lives National direct-to-consumer campaign, “VOQUEZNA Can Kick Some Acid,” underway across broadcast and streaming TV Management to host conference cal...
ACELYRIN, INC. Announces Leadership Transition
ACELYRIN, INC. Announces Leadership Transition Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D., MRCP, FRCP named Chief Medical Officer, Gil Labrucherie, the company’s Chief Financial Officer, additionally named Chief Business Officer, and Sanam Pangali named Chief Legal Officer and Head of People LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery...
AEON Biopharma Provides Update on Development Pipeline
AEON Biopharma Provides Update on Development Pipeline Includes two late-stage clinical programs and two early-stage clinical programs IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our early-stage clinical programs, we ...
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
MeiraGTx Reports First Quarter 2024 Financial and Operational Results - Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) - Clinical development milestones met and remain on track for the rest of the year for AAV-hA...
Creative Realities to Restructure Debt Through Revolving Credit Facili...
Creative Realities to Restructure Debt Through Revolving Credit Facility Provides Added Financial Flexibility and Path to Reduce Interest Going Forward LOUISVILLE, Ky., May 09, 2024 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, today announced that it had signed a non-binding commitment letter with First Merchants Bank (“First Merchants”) for a $20 million senior secured revolving credit facility (the “Revolver”) with a $5 million accordion feature. A portion of the ...
ProPhase Labs Announces Financial Results for the Three Months Ended M...
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. Pharmaloz Manufacturing explores strategic alternatives, including potential sale. Company announces major strategic AI initiative, Project ZenQ-AI, leveraging its massive global genomics database and patented discoveries in its BE-Smart Esophageal Cancer Diagnostic Test. BE-Smart Cancer Test continues to advance towards second half commercialization. Company to hold a conference call Thursday, May 9, 2024, at 11:00 AM ET...
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Del...
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-pers...
Stryker declares a $0.80 per share quarterly dividend
Stryker declares a $0.80 per share quarterly dividend Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the close of business on June 28, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and s...
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets ...
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresent...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.